Japan's Kirin, Kyowa Merge To Strengthen Biotechnology Focus
This article was originally published in PharmAsia News
Executive Summary
Kirin Holdings and Kyowa Hakko will seek to bring together each company's strength in biotech to create a global research and development-centered Japanese drug company. The two Tokyo-based companies announced a merger agreement Oct. 22, reflecting the ongoing consolidation of the Japanese drug industry